On 28 October 2026 HHS announced a draft enforcement discretion policy for six peptides compounded under section 503A: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. It was published in the Federal Register on 30 October 2026 (91 FR 68526, docket HHS-OASH-2026-0496).
Ask PeptideBlog about any peptide
What it says
HHS says it does not intend to take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians who compound these six, if conditions are met. They need a valid patient-specific prescription, one active ingredient per product, an ingredient from an FDA-registered CGMP manufacturer with a certificate of analysis showing the facility location, adverse event reporting to MedWatch and the states, the label “This is a compounded drug product. Not for resale.”, documented adequate bioavailability for oral forms, an FDA 510(k)-cleared syringe for any injectable, and compliance with the rest of the FD&C Act.
What it is not
It is not an FDA approval. It is not a Category 1 listing, so the six are still not on the 503A bulks list. It is not a proposed or final rule amending 21 CFR 216.23. It does not bind state boards of pharmacy. It stays in place until each peptide is addressed in a final rule, and HHS can withdraw it.
What it does not cover
503B outsourcing facilities are outside the notice. So is emideltide (DSIP), which the advisory committee voted against in July. Five other peptides have not yet had their second committee review: GHK-Cu (injectable), LL-37, Dihexa, PEG-MGF and Melanotan II. That meeting is expected before the end of February 2027, and no date has been published. This policy does not change their status.
How it got here
On 15 April 2026 FDA removed 12 peptides from Category 2 without moving them to Category 1. On 23 and 24 July 2026 the Pharmacy Compounding Advisory Committee, which is advisory only, recommended the six for the bulks list. The FDA peptide status guide tracks where each peptide stands.
What happens next
Comments are due 13 November 2026. A citizen petition from the Partnership for Safe Medicines opposing the policy was filed on 23 October 2026 (docket FDA-2026-P-13366), according to a law-firm analysis. For peptide-by-peptide routes, forms and the fine print, read the full analysis of the HHS policy. A separate site, The Weight Loss Atlas, also keeps a peptide compounding policy tracker.
Sources
- HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register, 30 October 2026. federalregister.gov. Evidence category: primary government document.
- Arnold & Porter. HHS Announces Draft Enforcement Discretion Policy Paving Way for Pharmacies to Compound Certain Peptides While FDA Rulemaking Is Pending. 2 November 2026. arnoldporter.com. Evidence category: law-firm analysis.
Educational reference only. This page documents a regulatory notice and is not medical or legal advice.